Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03894540 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
A Phase 1 study, sponsored by Ipsen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03894540 is a Phase 1 study that was terminated before completion, run by Ipsen. The registered enrollment target is 22 participants.
The verdict
NCT03894540, a Phase 1 study, was terminated before completion, sponsored by Ipsen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with advanced solid tumours and to evaluate food effect (Part D).
Interventions
- DRUG pembrolizumab
- DRUG paclitaxel
- DRUG IPN60090
- DRUG IPN60090 single administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03894540
The ClinicalTrials.gov registry entry for NCT03894540 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pembrolizumab is the first listed.
NCT03894540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03894540 about?
NCT03894540 is a clinical study titled "Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours". The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with adv...
What is the current status of trial NCT03894540?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-03-22. Estimated completion is 2020-12-21.
What interventions are being tested in trial NCT03894540?
The interventions under investigation include: pembrolizumab (DRUG), paclitaxel (DRUG), IPN60090 (DRUG), IPN60090 single administration (DRUG).
Who is sponsoring clinical trial NCT03894540?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.